Kailera Therapeutics, Inc. Fair Value, Option, Credit Risk, Gains (Losses) on Assets
Kailera Therapeutics, Inc. (KLRA) reported Fair Value, Option, Credit Risk, Gains (Losses) on Assets of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-26.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets · last filed 2026-05-26
- Kailera Therapeutics, Inc. fair value, option, credit risk, gains (losses) on assets for the quarter ending 2026-03-31 was $0.00.
- Kailera Therapeutics, Inc. fair value, option, credit risk, gains (losses) on assets for the quarter ending 2025-03-31 was $0.00.
| Period end | Fair Value, Option, Credit Risk, Gains (Losses) on Assets 3 month |
|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-26 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |